Raphael Pharmaceutical Inc. (RAPH) Form 10-Q — May 14, 2026
Raphael Pharmaceutical Inc. reported no revenue for the three months ended March 31, 2026, and a net loss of $229,000, or $0.01 per share. The company's cash position as of March 31, 2026, was only $1,000, raising substantial doubt about its ability to continue as a going concern. The decrease in net loss from $429,000 in the same period of 2025 to $229,000 in 2026 was primarily due to a reduction in research and development expenses and general and administrative costs.
Key figures
- Revenue
- 0
- Total Debt
- 1665
- Cash Position
- 1
Price after filing
Close on the filing date to close N calendar days later (from $1.40). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.